RSV Vaccines That Are FDA-Approved
RSV Antibody Treatment for Infants and Babies In 2023, the FDA approved the monoclonal antibody treatment nirsevimab (Beyfortus) from Sanofi and AstraZeneca to prevent RSV infection in newborns, infants, and…
RSV Antibody Treatment for Infants and Babies In 2023, the FDA approved the monoclonal antibody treatment nirsevimab (Beyfortus) from Sanofi and AstraZeneca to prevent RSV infection in newborns, infants, and…